Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-arm, Phase II Study of Zanubrutinib in Combination With GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma

NCT06918015 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT06918015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06918015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-arm, Phase II Study of Zanubrutinib in Combination With GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
Lead sponsor
Zhejiang Cancer Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 1, 2025
Completion date
May 1, 2030
Enrollment
58 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

btk inhibitors, follicular lymphoma, immunochemotherapy